FTSE MIB
34.264,59 +22,10 (+0,06%) Dow Jones
38.884,26 +31,99 (+0,08%) Nasdaq
16.332,56 -16,69 (-0,10%) Nikkei 225
38.202,37 -632,73 (-1,63%) Petrolio
77,56 -0,82 (-1,05%) Bitcoin EUR
57.927,24 -1.244,55 (-2,10%)
HUTCHMED (China) Limited (HMDCF)
| Chiusura precedente | 3,8150 |
| Aperto | 3,8150 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 3,8150 - 3,8150 |
| Intervallo di 52 settimane | 2,0510 - 3,9500 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | 3,257B |
| Beta (5 anni mensile) | 0,68 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0500 |
| Prossima data utili | 29 lug 2024 - 02 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireHUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain. Details of the presentations are as foll
- GlobeNewswire
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
- GlobeNewswire
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration non-small cell lung cancer (“NSCLC”), were presented during the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lu
